These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Schreibman T; Friedland G Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459 [TBL] [Abstract][Full Text] [Related]
33. Recovery of the immune system with antiretroviral therapy: the end of opportunism? Powderly WG; Landay A; Lederman MM JAMA; 1998 Jul; 280(1):72-7. PubMed ID: 9660367 [TBL] [Abstract][Full Text] [Related]
34. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Grant PM; Zolopa AR Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832 [TBL] [Abstract][Full Text] [Related]
35. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779 [TBL] [Abstract][Full Text] [Related]
36. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829 [TBL] [Abstract][Full Text] [Related]
37. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. Schnittman SM; Fox L AIDS Res Hum Retroviruses; 1997 Jul; 13(10):815-8. PubMed ID: 9197375 [TBL] [Abstract][Full Text] [Related]
38. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583 [TBL] [Abstract][Full Text] [Related]
39. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189 [TBL] [Abstract][Full Text] [Related]
40. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]